A New Chapter for Alzheimer’s Disease? The Future of Therapeutics
The Alzheimer’s community cheered in early July when the FDA approved donanemab (Kisunla) for the treatment of early Alzheimer’s disease.
Discover Michael's blog, where he shares his insights and expert analyses on the dynamic world of pharmaceuticals and healthcare. Stay updated with industry trends, and gain perspectives from an accomplished global pharmaceutical executive.